Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Avastin
Biotech
Outlook's eye disease drug fails to match Lucentis, sinking stock
The biotech brushed off the failure, noting positive details and vowing to seek FDA approval, but investors were less sanguine about the setback.
Nick Paul Taylor
Nov 27, 2024 8:40am
Overcoming resistance to cancer I-O by targeting macrophages
Aug 11, 2021 2:00pm
Roche's I-O antibody triplet shows promise in mouse tumor models
Jan 2, 2020 9:00am
VBL sees Avastin-VB-111 phase 3 combo flop in brain cancer
Mar 8, 2018 8:35am
Cancer Research UK in $63M clinical trial boost
Feb 15, 2018 3:49am
Roche splashes $1.7B in cash for Ignyta and entrectinib
Dec 22, 2017 4:21am
